300 The American Road
United States - Map
Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other serious diseases. Its products include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; Yttrium-90 labeled clivatuzumab tetraxetan, a therapeutic product candidate that completed a Phase Ib clinical trial for the treatment of pancreatic cancer; and Veltuzumab, a humanized anti-CD20 monoclonal antibody for the treatment of non-Hodgkin lymphoma (NHL). The companys products also comprise Milatuzumab, a transmembrane protein that is highly expressed in MM and other B-cell lymphomas and leukemias, and in certain solid tumors; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL; Labetuzumab, a proprietary humanized antibody, which is in Phase II clinical development stage, targets the carcinoembryonic antigen, CEACAM5; and hRS7, an internalizing humanized anti-epithelial glycoprotein-1 antibody. It also manufactures and commercializes LeukoScan, a diagnostic imaging system to determine the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers. The company has strategic partnerships and relationships with UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
|Immunomedics Inc.’s ISS Governance QuickScore as of Apr 1, 2014 is 3. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 1; Compensation: 4.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. David M. Goldenberg ,
Founder, Chairman, Chief Medical Officer, Chief Scientific Officer and Director of IBC Pharmaceuticals Inc
|Ms. Cynthia L. Sullivan ,
Chief Exec. Officer, Pres, Director and Pres of Ibc Pharmaceuticals Inc
|Mr. Gerard G. Gorman ,
|Mr. Peter Pfreundschuh ,
Chief Financial Officer and VP of Fin.
|Dr. Chau Cheng ,
Sr. Director of Investor Relations & Grant Management
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|